Jemperli is on a steep growth trajectory with GSK guiding to greater than £2 billion ($2.7 billion) peak monotherapy sales1
$343 million/£261 million in Q4 2025 sales2
>13% quarter-over-quarter growth rate
~$1.4 billion annualized run rate
$1.128 billion/£861 million in FY 2025 sales2
>89% year-over-year growth rate
Far greater than
$2.7 billion peak sales1
guidance from GSK
>$390 million
in annualized Jemperli royalties payable to Anaptys at GSK’s peak sales guidance as early as 20293
- CEO Emma Walmsley, 2025 JP Morgan CEO Series fireside chat, 9/11/2025, “there’s no change to our peak year sales overall ambition for Jemperli, that’s for sure, which is far more than £2 billion.”
- GSK Q4 2025 earnings presentation, US dollar conversion
- Anaptys expectation